Adele Busico
Tumori Foundation(US)Fondazione IRCCS Istituto Nazionale dei Tumori(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan(2018)399 cited
- → Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer(2016)180 cited
- → Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial(2022)123 cited
- → Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study(2017)117 cited
- → Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study(2017)108 cited
- → Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy(2019)107 cited
- → Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC(2018)105 cited
- → MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer(2016)101 cited
- → First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study(2017)98 cited
- → Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation(2013)84 cited